ES2962315T3 - Compuestos heterocíclicos bicíclicos sustituidos - Google Patents
Compuestos heterocíclicos bicíclicos sustituidos Download PDFInfo
- Publication number
- ES2962315T3 ES2962315T3 ES17733156T ES17733156T ES2962315T3 ES 2962315 T3 ES2962315 T3 ES 2962315T3 ES 17733156 T ES17733156 T ES 17733156T ES 17733156 T ES17733156 T ES 17733156T ES 2962315 T3 ES2962315 T3 ES 2962315T3
- Authority
- ES
- Spain
- Prior art keywords
- methyl
- oxo
- dihydroisobenzofuran
- pyrimidin
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325255P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028231 WO2017184662A1 (en) | 2016-04-20 | 2017-04-19 | Substituted bicyclic heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2962315T3 true ES2962315T3 (es) | 2024-03-18 |
Family
ID=59215932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17733156T Active ES2962315T3 (es) | 2016-04-20 | 2017-04-19 | Compuestos heterocíclicos bicíclicos sustituidos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10851108B2 (https=) |
| EP (1) | EP3445762B1 (https=) |
| JP (1) | JP6905993B2 (https=) |
| KR (1) | KR102417686B1 (https=) |
| CN (1) | CN109311874B (https=) |
| AU (1) | AU2017252546B2 (https=) |
| BR (1) | BR112018071548A2 (https=) |
| CA (1) | CA3021335A1 (https=) |
| EA (1) | EA037300B1 (https=) |
| ES (1) | ES2962315T3 (https=) |
| IL (1) | IL262448B (https=) |
| MX (1) | MX381425B (https=) |
| SG (1) | SG11201809173TA (https=) |
| WO (1) | WO2017184662A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10723723B2 (en) * | 2016-11-03 | 2020-07-28 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as ROMK channel inhibitors |
| EP3630752B1 (en) | 2017-06-01 | 2021-06-30 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
| WO2023107705A1 (en) | 2021-12-10 | 2023-06-15 | Incyte Corporation | Bicyclic amines as cdk12 inhibitors |
| TW202527931A (zh) * | 2023-11-08 | 2025-07-16 | 美商奧科坦特公司 | 視紫質的藥理校正劑及其用途 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8824291D0 (en) | 1988-10-17 | 1988-11-23 | Zambeletti Spa L | Novel use |
| DE102004020908A1 (de) | 2004-04-28 | 2005-11-17 | Grünenthal GmbH | Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen |
| US8247556B2 (en) | 2005-10-21 | 2012-08-21 | Amgen Inc. | Method for preparing 6-substituted-7-aza-indoles |
| WO2007052124A1 (en) | 2005-11-04 | 2007-05-10 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| ES2396160T3 (es) | 2006-12-14 | 2013-02-19 | Bayer Intellectual Property Gmbh | Derivados de DIHIDROPIRIDINA que utiliza como inhibidores de la proteina quinasa |
| US8673920B2 (en) * | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2010130773A2 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Benzoxazolone derivatives as aldosterone symthase inhibitors |
| DE102009022896A1 (de) | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| WO2012058116A1 (en) | 2010-10-27 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2632464B1 (en) | 2010-10-29 | 2015-04-29 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| AU2012299227A1 (en) | 2011-08-19 | 2014-02-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| MX2014002208A (es) | 2011-08-25 | 2014-05-28 | Hoffmann La Roche | Inhibidores de serina/treonina quinasa. |
| WO2013039802A1 (en) | 2011-09-16 | 2013-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| US8999990B2 (en) | 2011-10-25 | 2015-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2771004B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2773206B1 (en) | 2011-10-31 | 2018-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2773351B1 (en) | 2011-10-31 | 2017-08-23 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2013066714A1 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2790511B1 (en) | 2011-12-16 | 2016-09-14 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| BR112014015549A8 (pt) | 2011-12-22 | 2017-07-04 | Hoffmann La Roche | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção |
| AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
| WO2014015495A1 (en) | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| CN104781251B (zh) | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
| EP2925322B1 (en) * | 2012-11-29 | 2018-10-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2014089324A1 (en) | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Substituted cyclic compounds and methods of use |
| US9573961B2 (en) | 2012-12-19 | 2017-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2014126944A2 (en) | 2013-02-18 | 2014-08-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP2968288B1 (en) | 2013-03-15 | 2018-07-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| JP6103527B2 (ja) | 2013-04-17 | 2017-03-29 | 矢崎総業株式会社 | 余長吸収装置及びコイルユニット |
| FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3027625B1 (en) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure |
| WO2015065866A1 (en) | 2013-10-31 | 2015-05-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| EP3083573B1 (en) | 2013-12-18 | 2024-08-07 | Merck Sharp & Dohme LLC | Inhibitors of the renal outer medullary potassium channel |
| WO2015096035A1 (en) | 2013-12-24 | 2015-07-02 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| WO2015103756A1 (en) | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016008064A1 (en) | 2014-07-14 | 2016-01-21 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| MX2017000634A (es) | 2014-07-14 | 2017-05-01 | Merck Sharp & Dohme | Inhibidores del canal de potasio medularmente externo renal. |
| WO2016060941A1 (en) | 2014-10-14 | 2016-04-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016065582A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016065602A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
| WO2016065603A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016069428A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| KR20170090477A (ko) | 2014-12-08 | 2017-08-07 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 피리딘카복스아미드 유도체, 그의 제조 방법 및 그의 약학적 용도 |
| CN105693706B (zh) | 2014-12-10 | 2019-11-22 | 江苏恒瑞医药股份有限公司 | 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用 |
| WO2016122994A1 (en) | 2015-01-29 | 2016-08-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
-
2017
- 2017-04-19 BR BR112018071548-4A patent/BR112018071548A2/pt not_active Application Discontinuation
- 2017-04-19 ES ES17733156T patent/ES2962315T3/es active Active
- 2017-04-19 MX MX2018012840A patent/MX381425B/es unknown
- 2017-04-19 WO PCT/US2017/028231 patent/WO2017184662A1/en not_active Ceased
- 2017-04-19 AU AU2017252546A patent/AU2017252546B2/en not_active Expired - Fee Related
- 2017-04-19 EA EA201892382A patent/EA037300B1/ru not_active IP Right Cessation
- 2017-04-19 KR KR1020187033099A patent/KR102417686B1/ko active Active
- 2017-04-19 US US16/094,288 patent/US10851108B2/en active Active
- 2017-04-19 CA CA3021335A patent/CA3021335A1/en not_active Abandoned
- 2017-04-19 JP JP2018555138A patent/JP6905993B2/ja active Active
- 2017-04-19 SG SG11201809173TA patent/SG11201809173TA/en unknown
- 2017-04-19 CN CN201780036983.6A patent/CN109311874B/zh active Active
- 2017-04-19 EP EP17733156.8A patent/EP3445762B1/en active Active
-
2018
- 2018-10-17 IL IL262448A patent/IL262448B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017184662A1 (en) | 2017-10-26 |
| MX2018012840A (es) | 2019-03-11 |
| SG11201809173TA (en) | 2018-11-29 |
| CN109311874B (zh) | 2021-07-30 |
| EA037300B1 (ru) | 2021-03-05 |
| EP3445762A1 (en) | 2019-02-27 |
| US20190127380A1 (en) | 2019-05-02 |
| EA201892382A1 (ru) | 2019-03-29 |
| US10851108B2 (en) | 2020-12-01 |
| BR112018071548A2 (pt) | 2019-04-16 |
| IL262448A (en) | 2018-12-31 |
| MX381425B (es) | 2025-03-12 |
| CA3021335A1 (en) | 2017-10-26 |
| IL262448B (en) | 2020-08-31 |
| AU2017252546B2 (en) | 2021-07-29 |
| KR102417686B1 (ko) | 2022-07-07 |
| CN109311874A (zh) | 2019-02-05 |
| KR20180134999A (ko) | 2018-12-19 |
| JP6905993B2 (ja) | 2021-07-21 |
| JP2019515911A (ja) | 2019-06-13 |
| EP3445762B1 (en) | 2023-09-13 |
| AU2017252546A1 (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2977657T3 (es) | Compuestos de 6-azaindol | |
| ES2943028T3 (es) | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de PD-L1 | |
| ES2945435T3 (es) | Compuestos de indol sustituidos | |
| ES2879995T3 (es) | Métodos para el tratamiento de la enfermedad de Huntington | |
| BR112020026545A2 (pt) | Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington | |
| TW202110843A (zh) | 含氮雜環類衍生物調節劑、其製備方法和應用 | |
| ES2999539T3 (en) | 1h-benzo[d]imidazole derivatives as tlr9 inhibitors for the treatment of fibrosis | |
| EP4223369A1 (en) | Immunomodulator compounds and methods of use | |
| BR112020019373A2 (pt) | Compostos para o tratamento da doença de hutington | |
| ES2962315T3 (es) | Compuestos heterocíclicos bicíclicos sustituidos | |
| JP2014051516A (ja) | タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体 | |
| ES3034264T3 (en) | 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis | |
| TW202321247A (zh) | 用於治療杭丁頓氏舞蹈症的雜芳基化合物 | |
| TW201024298A (en) | (R)-3-(N,N-dimethylamino)pyrrolidine derivatives | |
| ES2908252T3 (es) | Derivados de piridinona y su uso como inhibidores selectivos de ALK-2 | |
| JP7813775B2 (ja) | 線維症の処置のためのｔｌｒ９の阻害剤としてのイミダゾ［１，２－ａ］ピリジンおよび［１，２，４］トリアゾロ［１，５－ａ］ピリジン誘導体 | |
| HK40107097A (zh) | 作为白介素-1活性抑制剂的新型经取代的磺酰脲化合物 | |
| CA3249905A1 (en) | Substituted bicyclic heteroaryl compounds useful as TLR9 inhibitors | |
| WO2025207755A1 (en) | Quinolizinones as pi3k inhibitors | |
| CN120390740A (zh) | 作为PI3Kα抑制剂的杂环化合物 | |
| HK1238629B (zh) | 作为pi3k抑制剂的吡啶并[1，2-a]嘧啶酮类似物 |